PSTV logo

PLUS THERAPEUTICS INC

PSTVNASDAQ
US Equity
$3.90▲ $0.32 (+8.79%)
Market closed · at close
🔔
Track PSTV
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 8.8%
7d—
14d—
30d—
ytd▼ 69.5%
1y▼ 71.1%
🏦Market Cap
—
📈Revenue Growth (YoY)
5038.4%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
2.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$3.65 – $3.90
52-Week Range
$1.49 – $18.88
Volume (shares)
1,434
Avg Volume (shares)
—
Shares Outstanding
—
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$5M
Last Q Revenue
$411,000
P/E Ratio
—
P/S Ratio
2.0x
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+1318622.0%
PSTV logo

PLUS THERAPEUTICS INC

PSTV
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$5M▼ −10.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.5%▲ +7.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$15M▲ +4.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$21M▲ +94.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.1M▲ +1318622.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▲ +$11M YoY
StockOtter · stockotter.space

About PLUS THERAPEUTICS INC

Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.